Naoki Okumura

Direktor/Vorstandsmitglied bei ActualEyes, Inc.

Technology Services

Aktive Beziehungen

Name	Geschlecht	Alter	Unternehmensverbindungen	Zusammenarbeit
Iku Sugioka	M	-	ActualEyes, Inc. ActualEyes, Inc. Packaged SoftwareTechnology Services ActualEyes, Inc. is a Japanese company that conducts research and development of products such as regenerative medicine for corneal endothelial disease. The company is based in Kyotanabe, Japan. The company's mission is to deliver the desired light to patients suffering from visual impairment and to ensure and promptly implement a new treatment society. The company was founded in 2018. The CEO is Iku Sugioka.	-
Yuki Hasegawa	M	46	ActualEyes, Inc. ActualEyes, Inc. Packaged SoftwareTechnology Services ActualEyes, Inc. is a Japanese company that conducts research and development of products such as regenerative medicine for corneal endothelial disease. The company is based in Kyotanabe, Japan. The company's mission is to deliver the desired light to patients suffering from visual impairment and to ensure and promptly implement a new treatment society. The company was founded in 2018. The CEO is Iku Sugioka.	-
Masahiko Kato	M	-	ActualEyes, Inc. ActualEyes, Inc. Packaged SoftwareTechnology Services ActualEyes, Inc. is a Japanese company that conducts research and development of products such as regenerative medicine for corneal endothelial disease. The company is based in Kyotanabe, Japan. The company's mission is to deliver the desired light to patients suffering from visual impairment and to ensure and promptly implement a new treatment society. The company was founded in 2018. The CEO is Iku Sugioka.	-
Noriko Koizumi	M	55	ActualEyes, Inc. ActualEyes, Inc. Packaged SoftwareTechnology Services ActualEyes, Inc. is a Japanese company that conducts research and development of products such as regenerative medicine for corneal endothelial disease. The company is based in Kyotanabe, Japan. The company's mission is to deliver the desired light to patients suffering from visual impairment and to ensure and promptly implement a new treatment society. The company was founded in 2018. The CEO is Iku Sugioka.	6 Jahre